Hepatitis C Treatment Snapshots: Daclatasvir

Hepatitis C Treatment Snapshots: Daclatasvir

For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.

/ News

Share the Post

Related Posts

The Updated Pricing of Ledipasvir and Sofosbuvir Co-formulated tablets
New WHO guideline on care and treatment of chronic hepatitis C
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
Patent Situation of The Key Product for Treatment of Hepatitis C: DACLASTAVIR – WHO working paper, revised version, Oct 2014
Hepatitis C vaccine fails to prevent chronic infections
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Progress report on access to hepatitis C treatment, WHO March 2018
Community group taking actions to enable greater access for generic HCV treatment